Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Lymphoma

Free Subscription 15.12.2025 1 BMC Neurol 1 Bone Marrow Transplant 2 Br J Cancer 2 Eur J Haematol 1 Haematologica 1 Hum Pathol 4 J Clin Oncol 1 J Natl Cancer Inst 5 Leuk Lymphoma 1 Mod Pathol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. BAKHARJI A, Al Hijab A, Al Harbi T, Ali EN, et al
   Central pontine myelinolysis in diffuse large B-cell lymphoma, a case series and literature review.
   BMC Neurol. 2025 Dec 4. doi: 10.1186/s12883-025-04564.
   PubMed        
   
   

   
   Bone Marrow Transplant

2. EASTON N, Goldfarb DG, El-Naas A, Kam R, et al
   Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis.
   Bone Marrow Transplant. 2025 Dec 5. doi: 10.1038/s41409-025-02758.
   PubMed        
   
   

   
   Br J Cancer

3. ZHANG H, Liu L, Zhang X, Chen P, et al
   Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality.
   Br J Cancer. 2025;133:1907-1915.
   PubMed         Abstract available
   
   
4. ALMANZA-AGUILERA E, Guananga-Alvarez D, Benavente Y, Nieters A, et al
   Intake of total, classes, and subclasses of (poly)phenols and risk of lymphoid neoplasms: a prospective analysis in the EPIC cohort.
   Br J Cancer. 2025;133:1864-1871.
   PubMed         Abstract available
   
   

   
   Eur J Haematol

5. ALSOUQI A, Huang Y, Christian B, Reneau J, et al
   A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation.
   Eur J Haematol. 2025 Dec 9. doi: 10.1111/ejh.70064.
   PubMed        
   
   
6. MUNKSGAARD L, Pedersen LM, Munksgaard ASE, Gjerdrum LMR, et al
   Time to Next Treatment Within 24 Months (TTNT24) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia: A Population-Based Observational Study.
   Eur J Haematol. 2025 Dec 4. doi: 10.1111/ejh.70073.
   PubMed         Abstract available
   
   

   
   Haematologica

7. KAMA K, Treiber H, Kutilina A, Trefz S, et al
   Rituximab, Dexamethasone, Etoposide, Ifosfamide and Carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma - a retrospective multicentre clinical study.
   Haematologica. 2025 Dec 11. doi: 10.3324/haematol.2025.287982.
   PubMed         Abstract available
   
   

   
   Hum Pathol

8. KING RL, Ondrejka SJ, Cook JR
   Three Practice Updates in Non-Hodgkin Lymphoma for 2026.
   Hum Pathol. 2025 Dec 11:106012. doi: 10.1016/j.humpath.2025.106012.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

9. WOYACH JA, Qiu L, Grosicki S, Wrobel T, et al
   Pirtobrutinib Versus Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
   J Clin Oncol. 2025 Dec 7:JCO2502477. doi: 10.1200/JCO-25-02477.
   PubMed         Abstract available
   
   
10. JURCZAK W, Kwiatek M, Czyz J, Roberto de Mattos E, et al
    BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    J Clin Oncol. 2025 Dec 9:JCO2502380. doi: 10.1200/JCO-25-02380.
    PubMed         Abstract available
    
    
11. POPHALI PA, Kenkre VP, Hayes CA
    Bridging the Gap: Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma: Long-Term Benefit, Yet Real-World Complexity.
    J Clin Oncol. 2025 Dec 10:JCO2502323. doi: 10.1200/JCO-25-02323.
    PubMed        
    
    
12. WANG S, Nijland M, Strobbe L, Oosterveld M, et al
    Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma.
    J Clin Oncol. 2025 Dec 12:JCO2501712. doi: 10.1200/JCO-25-01712.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

13. TAO J, Luo Q, Haas CB, Mbulaiteye SM, et al
    Risk of lymphoma among people with HIV in the United States, 2001-2019.
    J Natl Cancer Inst. 2025;117:2505-2512.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

14. LIU J, Zhou J, Xi Z, Liu K, et al
    Survival outcomes and failure patterns in stage I/II extranodal NK/T-cell lymphoma after involved site radiotherapy with asparaginase-based chemotherapy-a retrospective study.
    Leuk Lymphoma. 2025 Dec 13:1-9. doi: 10.1080/10428194.2025.2600639.
    PubMed         Abstract available
    
    
15. STEGEMANN M, Macherndl-Spandl S, Mairhofer M, Kaltenbrunner S, et al
    Simultaneous auto-transplant and CD19 CAR T-cell 2nd line therapy followed by CD20 x CD3 bispecific antibody for refractory Burkitt lymphoma, a case report.
    Leuk Lymphoma. 2025 Dec 8:1-5. doi: 10.1080/10428194.2025.2591779.
    PubMed        
    
    
16. OLUWOLE OO, Wade SW, Smith NJ, Spousta T, et al
    Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.
    Leuk Lymphoma. 2025 Dec 8:1-5. doi: 10.1080/10428194.2025.2584686.
    PubMed        
    
    
17. FAISAL MS, Anampa Guzman A, Attwood K, Torka P, et al
    Treatment of older adults with peripheral T cell lymphoma (PTCL) amidst a changing therapeutic landscape: a 20-year single institution experience.
    Leuk Lymphoma. 2025 Dec 5:1-5. doi: 10.1080/10428194.2025.2589932.
    PubMed        
    
    
18. BRAUN T, Keppel M, Dechow A, Pflug N, et al
    Characteristics, patterns of care and outcomes of patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis: a single-center retrospective analysis.
    Leuk Lymphoma. 2025 Dec 5:1-4. doi: 10.1080/10428194.2025.2594062.
    PubMed        
    
    

    
    Mod Pathol

19. NAGASE S, Nakamura N, Kikuti YY, Carreras J, et al
    Redefining the Spectrum of EBV-Positive Diffuse Large B-Cell Lymphoma and EBV-Positive Classic Hodgkin Lymphoma.
    Mod Pathol. 2025 Dec 8:100950. doi: 10.1016/j.modpat.2025.100950.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.